Butler, "Cyclin-dependent kinase
5 promotes pancreatic beta-cell survival via Fak-Akt signaling pathways," Diabetes, vol.
. Cyclin-dependent kinases
(CDK) are serine/threonine protein kinases that bind to cyclin to mediate the phosphorylation reactions that are associated with the progression and regulation of the cell cycle .
Chan et al., "The cyclin-dependent kinase
inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis," Cell Cycle, vol.
Abbreviations GC: Gastric cancer OD: Optical density CDK: Cyclin-dependent kinase
PBS: Phosphate-buffered saline PI: Propidium iodide.
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases
. Cell 75, 805-816.
It prevents premature activation of cyclin E-cyclin-dependent kinase 2 in G1 and promotes the assembly and activation of D-type cyclin-dependent kinases
. (20) Although the p27 gene is rarely mutated in human cancers, the action of p27 is impaired through a variety of mechanisms including proteolysis.
Subsequent work revealed that let-7 regulates a number of other oncogenes, including CCND2 (cyclin D2), CDK6 (cyclin-dependent kinase
6), CDC25 [cell division cycle 25 homolog C (S.
inhibitors, p21, and p27 play pivotal roles in mammalian cell cycle regulation (Das et al.
The growth inhibitory effect of ALA is not due to induction of apoptosis but instead is associated with an increase in the half-life of the cyclin-dependent kinase
Results.--The ratio values considered significant (<0.5 or >1.5) suggest that genes up-regulated in parathyroid adenoma are those responsible for blood vessel angiogenesis and genes belonging to the cyclin-dependent kinase
Syros Pharmaceuticals announced preclinical data on SY-1365, its first-in-class selective cyclin-dependent kinase
7 inhibitor, showing synergistic anti-tumor activity in combination with carboplatin, a standard-of-care therapy, in models of ovarian cancer and providing a mechanistic rationale for the ongoing investigation of the combination in the Phase 1 clinical trial of SY-1365.
Alvocidib is a small molecule inhibitor of cyclin-dependent kinase
9 (CDK9) that controls the expression of a survival factor MCL-1, while Venetoclax is a small molecule inhibitor of B-cell lymphoma-2 (BCL-2).